Faron Pharma just dropped some wild early trial results for their new cancer drug combo—patients with tough-to-treat bone marrow disorders are living way longer than expected! Median survival jumped from 5-6 months to 14.5 months, and some newly diagnosed folks with a tricky gene mutation saw a 70% complete remission rate. Plus, over half became transfusion-free. No treatment-related deaths, and the safety profile looks great. Next up: a pivotal phase III trial. Fingers crossed! #Health #BodyHealth #CancerResearch